Zegfrovy

News

Dizal set to bring lung cancer drug Zegfrovy to US

Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.

News

NHS "isn't delivering equitable care for rare diseases"

A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks